---
layout: post
title: "Elite Laboratories, Inc., et al.; Withdrawal of Approval of 23 Abbreviated New Drug Applications"
date: 2026-02-05 19:08:03 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-00076
original_published: 2020-01-08 00:00:00 +0000
significance: 8.00
---

# Elite Laboratories, Inc., et al.; Withdrawal of Approval of 23 Abbreviated New Drug Applications

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** January 08, 2020 00:00 UTC
**Document Number:** 2020-00076

## Summary

The Food and Drug Administration (FDA or Agency) is withdrawing approval of 23 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/01/08/2020-00076/elite-laboratories-inc-et-al-withdrawal-of-approval-of-23-abbreviated-new-drug-applications)
- API: https://www.federalregister.gov/api/v1/documents/2020-00076

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
